GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaEngine Inc (ROCO:4162) » Definitions » Deferred Policy Acquisition Costs

PharmaEngine (ROCO:4162) Deferred Policy Acquisition Costs


View and export this data going back to 2012. Start your Free Trial

What is PharmaEngine Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


PharmaEngine Business Description

Industry
Traded in Other Exchanges
N/A
Address
10 Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its projects pipeline are: ONIVYDE was approved by the U.S. FDA, Taiwan FDA, and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; and PEP07. It generates the revenue from Sales of goods.